Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.

@article{Blagden2015FinalRO,
  title={Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.},
  author={S. Blagden and I. Rizzuto and C. Stavraka and D. O'Shea and P. Suppiah and M. Patel and A. Sukumaran and Naomi Loyse and N. Bharwani and A. Rockall and H. Gabra and M. El-Bahrawy and H. Wasan and R. Leonard and Nagy A. Habib and J. Gribben and Essam A Ghazaly and C. McGuigan},
  journal={Journal of Clinical Oncology},
  year={2015},
  volume={33},
  pages={2514-2514}
}
  • S. Blagden, I. Rizzuto, +15 authors C. McGuigan
  • Published 2015
  • Medicine
  • Journal of Clinical Oncology
  • 2514 Background: NUC-1031 is a first-in-class nucleotide analogue utilising phosphoramidate chemistry to enhance anti-cancer efficacy and safety. In preclinical studies NUC-1031 demonstrated potent anti-cancer activity, generating high intracellular levels of the active cytotoxic di-fluoro-deoxycytidine triphosphate (dFdCTP) by overcoming key drug resistance mechanisms associated with nucleoside analogues. Methods: This study was comprised of 1) dose escalation part: 3–8 patients (pts) per… CONTINUE READING
    8 Citations
    Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.
    • 32
    • PDF
    Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014–2017)
    • 20
    Phosphoramidates and phosphonamidates (ProTides) with antiviral activity
    • 27
    • PDF
    Synthesis and biological evaluation of 6-substituted-5-fluorouridine ProTides.
    • 4
    • PDF
    The ProTide Prodrug Technology: From the Concept to the Clinic
    • 63
    • PDF